FDA
-
-
-
-
-
-
-
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease
-
-
-
-
-
-
-
scPharmaceuticals (SCPH) Reports Positive Topline Study Results for SCP-111
-
-
-
-
-
-
-
scPharmaceuticals Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update
-
-
-
-
-
-
-
scPharmaceuticals Provides FUROSCIX® (furosemide injection) Commercial Update
-
-
-
-
-
-
-
scPharmaceuticals (SCPH) Announces FDA Approval of FUROSCIX, the First and Only Self-administered, Subcutaneous Loop Diuretic for the At-home Treatment of Congestion in Chronic Heart Failure
-
-
-
-
-
-
-
scPharmaceuticals Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
-
-
-
-
-
-
-
scPharmaceuticals Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

